Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659103 | 0.85 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL657909 | 0.81 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL657835 | 0.77 | RBP4 (0.52) | TRPV1DRD2DRD3 | |
| SCHEMBL12506473 | 0.76 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL287641 | 0.73 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL10186767 | 0.72 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL660311 | 0.71 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL288083 | 0.71 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL659584 | 0.71 | MAPK1 (0.40) | TRPV1DRD2DRD3 | |
| SCHEMBL287653 | 0.70 | TRPV1 (0.79) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606033-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2013-06-26 | — | — | EP | claimed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | claimed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| EP-2606033-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | TRPV1 1/4885DRD2 1328/4885DRD3 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.